Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
1. A method for screening an isoform-selective TGFβ1 inhibitor suitable for therapeutic use, the method comprising:
i) providing an antibody that specifically binds each of: human LTBP1-proTGFβ1, human LTBP3-proTGFβ1, human GARP-proTGFβ1 and human LRRC33-proTGFβ1 complexes with a K D ≤1 nM,
ii) carrying out an in vivo efficacy study in a preclinical animal model, wherein the preclinical animal model is a syngeneic tumor model that recapitulates a human condition, wherein the antibody is administered to the preclinical animal model at a dosage of about 10 mg/kg/week or less in combination with an immune checkpoint inhibitor, wherein the in vivo efficacy study comprises measurement of tumor volume in the animal model, and selecting the antibody as achieving efficacy when the tumor volume is less than 25% of endpoint tumor volume in the preclinical animal model;
iii) carrying out a cardiovascular toxicology study in a preclinical model that is sensitive to pharmacological inhibition of TGFβ, to determine a maximally tolerated and/or minimum toxic amount of the antibody, wherein the cardiovascular toxicity comprises a cardiac lesion, a valvulopathy, hyperplasia in aortic valve, right AV valve or left AV valve, inflammation in aortic valve, left AV valve or ascending aorta, hemorrhage in ascending aorta, aortic valve or left AV valve, and/or connective tissue degeneration in ascending aorta; wherein the antibody is administered to the animal model at a dosage of about 10 mg/kg/week or less; and selecting the antibody as lacking cardiovascular toxicity when the maximally tolerated amount or minimum toxic amount is achieved with administration of the antibody at a dosage of greater than 10 mg/kg/week;
(iv) selecting the antibody as a therapeutic candidate if the antibody is selected as achieving efficacy in step (ii), and if the antibody is selected as lacking cardiovascular toxicity in step (iii).
2. The method according to claim 1 , wherein the antibody is selected as lacking cardiovascular toxicity when the maximally tolerated amount or minimum toxic amount is achieved with administration of the antibody at a dosage of at least 100 mg/kg/week.
3. The method of claim 1 , wherein the syngeneic tumor model that recapitulates a human condition comprises a Cloudman S91 model or an MBT-2 tumor model.
4. The method of claim 1 , wherein endpoint tumor volume is 2,000 mm 3 .
5. The method of claim 1 , wherein the in vivo efficacy study performed in the preclinical model further comprises immunohistochemical analyses, measurement of tumor growth, regression of tumor volume, regression of tumor growth, incidence of regression responses, or magnitude of regression responses.